Related Experiment Video
Updated: Jan 7, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Serum JKAP as a potential prognostic biomarker in acute coronary syndrome patients undergoing percutaneous coronary
1Department of Cardiology, Provincial Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Insights
JNK pathway-associated phosphatase (JKAP) levels are lower in acute coronary syndrome (ACS) patients and increase after percutaneous coronary intervention (PCI). JKAP shows potential as a prognostic biomarker for predicting major adverse cardiac events and physical performance in ACS patients post-PCI.
Area of Science:
- Immunology
- Cardiology
- Biochemistry
Background:
- JNK pathway-associated phosphatase (JKAP) knockdown influences CD4+ T-cell differentiation and atherosclerotic progression.
- CD4+ T-cell subtypes are dysregulated in acute coronary syndrome (ACS) patients post-percutaneous coronary intervention (PCI) and may serve as prognostic biomarkers.
Purpose of the Study:
- To investigate the correlation between JKAP levels and CD4+ T-cell subtypes.
- To evaluate JKAP as a prognostic biomarker for clinical outcomes in ACS patients undergoing PCI.
Main Methods:
- Serum JKAP levels were measured in 173 ACS patients before and 1 month after PCI, and in 32 healthy controls using ELISA.
- Short Physical Performance Battery (SPPB) scores and major adverse cardiac event (MACE) data were collected.
Main Results:
- ACS patients had significantly lower JKAP levels than controls; levels increased post-PCI.
- JKAP negatively correlated with Th17 and Th1 cells.
- JKAP levels before and after PCI effectively predicted MACE risk and, to a lesser extent, SPPB scores.
Conclusions:
- JKAP levels are altered in ACS patients and change after PCI.
- JKAP serves as an independent predictor of MACE risk and physical performance post-PCI.
- JKAP shows promise as a prognostic biomarker for ACS patients undergoing PCI.
Objective:
Our previous studies revealed that knockdown of JNK pathway-associated phosphatase (JKAP) facilitates atherosclerotic progression by regulating CD4+ T-cell differentiation. Moreover, CD4+ T-cell subtypes are dysregulated and can serve as a prognosis biomarker in acute coronary syndrome (ACS) patients who have undergone percutaneous coronary intervention (PCI). This study aims to further investigate the correlation between JKAP with CD4+ T-cell subtypes and prognosis in ACS patients who have undergone PCI.
Methods:
This study included 173 ACS patients, for whom serum JKAP levels were detected before PCI and 1 month (M1) after PCI via an enzyme-linked immunosorbent assay. Short physical performance battery (SPPB) scores at M1 and major adverse cardiac event (MACE) data were collected. Moreover, serum JKAP levels were detected in 32 healthy control subjects.
Results:
JKAP levels were significantly lower in ACS patients vs. healthy control subjects (P < 0.001) and were increased at M1 after PCI vs. before PCI in ACS patients (P < 0.001). JKAP negatively correlated with T-helper (Th)17 cells (P = 0.002) and tended to negatively associate with Th1 cells (P = 0.060), but did not correlate with Th2 or T-regulatory cells. Importantly, JKAP before PCI and at M1 after PCI showed good values in predicting MACE risk via receiver operating curve analyses [area under curve (AUC) = 0.721, AUC = 0.778, respectively]; however, JKAP demonstrated relatively weaker values in predicting an SPPB score of ≤6 points at M1 (AUC = 0.638, AUC = 0.649, respectively). Multivariable analyses revealed that JKAP at M1 after PCI independently predicted a lower risk of MACE (P = 0.045) and an SPPB score of ≤6 points at M1 (P = 0.025).
Conclusion:
JKAP may serve as a prognostic biomarker in ACS patients who have undergone PCI.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Acute Coronary Syndrome I: Introduction
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention